AllianceBernstein’s Edgewise Therapeutics EWTX Stock Holding History

AllianceBernstein’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.7M	Buy	2,119,024 +396,855	+23%	+$13.7M	0.02%	527
2026 Q1	$42.7M	Buy	1,722,169 +685,999	+66%	+$19.8M	0.01%	649
2025 Q4	$25.7M	Buy	1,036,170 +958,910	+1,241%	+$19.2M	0.01%	847
2025 Q3	$1.25M	Hold	77,260	–	–	﹤0.01%	2239
2025 Q2	$1.01M	Hold	77,260	–	–	﹤0.01%	2279
2025 Q1	$1.7M	Hold	77,260	–	–	﹤0.01%	1989
2024 Q4	$2.06M	Buy	77,260 +1,300	+2%	+$41.4K	﹤0.01%	1942
2024 Q3	$2.03M	Sell	75,960 -4,400	-5%	-$87.5K	﹤0.01%	1963
2024 Q2	$1.45M	Buy	80,360 +24,260	+43%	+$423K	﹤0.01%	2121
2024 Q1	$1.02M	Buy	56,100 +18,680	+50%	+$297K	﹤0.01%	2253
2023 Q4	$409K	Buy	37,420 +2,320	+7%	+$16.3K	﹤0.01%	2708
2023 Q3	$201K	Buy	35,100 +1,370	+4%	+$9.31K	﹤0.01%	2958
2023 Q2	$261K	Buy	33,730 +7,930	+31%	+$66.9K	﹤0.01%	2912
2023 Q1	$172K	Buy	25,800 +2,900	+13%	+$26.9K	﹤0.01%	2948
2022 Q4	$205K	Buy	22,900 +10,200	+80%	+$95.6K	﹤0.01%	2998
2022 Q3	$125K	Buy	+12,700	New	+$128K	﹤0.01%	3100

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's EWTX Position: Q2 2026 in Review

AllianceBernstein increased its Edgewise Therapeutics (EWTX) stake by 23% in Q2 2026, buying an estimated $13.7M and bringing the position to 2,119,024 shares worth $66.7M. The position accounts for 0.02% of the portfolio, ranked #527.

AllianceBernstein first reported a position in EWTX in Q3 2022 and has held it in 16 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

AllianceBernstein held 2,119,024 shares of Edgewise Therapeutics worth $66.7M as of Q2 2026.
AllianceBernstein bought 396,855 Edgewise Therapeutics shares in Q2 2026, an estimated $13.7M.
Edgewise Therapeutics made up 0.02% of AllianceBernstein's portfolio in Q2 2026, its #527 holding.
AllianceBernstein first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 16 quarters since.
223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.